BNTX (BioNTech SE) Valuation — rNPV Sum-of-the-Parts, August 2026

Equity Research Note — rNPV Sum-of-the-Parts Valuation

26 August 2026 | Prices as of 25 August 2026 close | EUR/USD 1.1667

1. Thesis in one paragraph

BioNTech screens as the cheapest large-cap biotech on enterprise value: USD 28.6B market capitalisation against USD 18.8B of net cash implies an EV of just USD 9.8B for a 14-pivotal-trial oncology pipeline. That screen is misleading. The cash is not a floor, it is a pre-committed development budget. Adjusted operating expenses of EUR 2.7-3.1B run against EUR 1.6-1.9B of guided revenue, and the net present value of cash burn to breakeven is negative USD 7.5B. Adjusting for that, the balance sheet is worth approximately USD 45 per share, not USD 75. On a probability-weighted net asset value the shares are worth USD 78. At USD 114 the market is requiring the lead asset, pumitamig, to reach worldwide peak sales larger than Keytruda.

2. Verified position

All balance sheet data verified against Form 6-K for the period ended 30 June 2026, filed 4 August 2026.

Item	Value
Price (25 Aug 2026)	USD 114.05
Shares outstanding (30 Jun)	251,204,366
Market capitalisation	USD 28.6B
Cash, equivalents and securities	EUR 16,634.2m
of which cash and equivalents	EUR 9,741.0m
of which current securities	EUR 5,035.1m
of which non-current securities	EUR 1,858.1m
Total debt (leases, loans, other financial)	EUR 484.4m
Net cash (66% of market cap)	USD 18.84B
Implied enterprise value	USD 9.8B
FY26 revenue guidance	EUR 1.6-1.9B (cut from 2.0-2.3B)
FY26 adjusted R&D	EUR 2.0-2.3B (cut from 2.2-2.5B)
FY26 adjusted SG&A	EUR 700-800m
H1 2026 adjusted net loss	EUR 1,056.9m
Buyback	USD 1.0B to May 2027; 1.69m ADS at USD 89.50 in Q2

Guidance cut drivers, per the filing: softer than anticipated global COVID-19 vaccine demand; existing vaccine inventory in Germany to be used in the 2026 vaccination season; and out-licensed R&D milestone revenue no longer expected in 2026.

3. WACC from first principles

Input	Value
Risk-free rate (US 10Y) — UNVERIFIED	4.75%
Equity risk premium (Damodaran mature market)	4.50%
Unlevered beta, Drugs (Biotechnology)	1.28
Debt / equity	1.97%
Levered beta (Hamada)	1.299
Cost of equity (CAPM)	10.60%
WACC	10.47%

The company is effectively all-equity and net cash, so WACC collapses to cost of equity. Sensitivity: a 4.00% risk-free rate gives 9.73%; a 5.50% risk-free rate gives 11.21%. Note the asymmetry — with bond yields elevated, the error runs against the valuation, not for it.

4. The cash is not free

Every bull case on BNTX treats EUR 16.6B as a hard floor. It is a development budget already spoken for. Modelled net cash burn to breakeven:

Year	Net cash burn (EUR B)
2026	1.85
2027	2.00
2028	1.85
2029	1.40
2030	0.70
2031	0.10
NPV at 10.47%	-USD 7.49B

This converts USD 18.84B of net cash into approximately USD 11.4B of spendable value, or USD 45.20 per share of hard floor — not the USD 75 per share the gross cash implies. The treatment is conservative in one direction: the full corporate burn is charged, while zero value is assigned to preclinical programmes, CAR-T (BNT211), infectious disease, or the acquired CureVac estate.

5. rNPV sum-of-the-parts, three scenarios

Risk-adjusted NPV of BioNTech's after-tax profit share per asset, in USD billions. Ramp 6 years, plateau 5 years, then 15% annual decay. Probability of success applied explicitly; discount rate not inflated a second time.

Asset (BioNTech economics)	Bear	Base	Bull
Pumitamig, PD-L1xVEGF, BMS 50/50	0.33	2.85	10.03
Gotistobart, CTLA-4	0.11	0.66	1.94
Trastuzumab pamirtecan, HER2 ADC	0.34	1.30	3.21
Elfetabart drozuntecan, B7-H3 ADC	0.07	0.49	2.04
mRNA INT (autogene cevumeran and others)	0.05	0.43	2.04
Pipeline rNPV	0.90	5.74	19.26
Net cash	18.84	18.84	18.84
NPV of cash burn	-7.49	-7.49	-7.49
COVID-19 annuity	1.60	1.60	1.60
Net asset value (USD B)	13.86	18.69	32.21
Per share (USD)	55.16	74.42	128.23

Base case pumitamig assumes USD 9B worldwide peak sales, 40% probability of success, 2030 launch, 55% operating margin, 50% profit share.

6. Reverse check: what the price demands

Holding all non-pumitamig assets at base case, the USD 28.6B market capitalisation requires USD 12.8B of pumitamig rNPV alone. Back-solving for the peak sales that implies:

Probability of success assumed	Required worldwide peak sales
30%	USD 53.9B
40%	USD 40.4B
50%	USD 32.3B
60%	USD 26.9B
70%	USD 23.1B

Keytruda peaks at roughly USD 30B. At a 50% probability of success, today's price requires pumitamig to become larger than the best-selling drug in pharmaceutical history — on the strength of Phase 2 data. That is the sanity check failing.

The conclusion is robust to the input I am least confident in. Varying base case pumitamig peak sales from USD 5B to USD 17B and probability of success from 30% to 60% moves the probability-weighted fair value only from USD 75 to USD 88. Every cell sits below USD 114.

Peak / PoS	30%	40%	50%	60%
USD 5B	75	76	77	78
USD 9B	77	78	80	81
USD 13B	79	81	83	84
USD 17B	81	83	85	88

Burn is the more sensitive lever. Base case net asset value moves from USD 65 to USD 83 per share across a plus or minus 30% burn band. Every USD 1B of incremental NPV burn costs approximately USD 4 per share.

7. Peer relative valuation

Metric	BNTX	MRNA	SMMT
Price (25 Aug 2026)	114.05	158.83	13.36
Day move	+1.09%	+14.36%	+4.95%
Market cap (USD B)	28.6	63.0	approx 9.9
Net cash (USD B)	+18.8	+5.4	modest
Enterprise value (USD B)	9.8	57.6	approx 8-9
Cash as % of market cap	66%	9%	—
EV / FY26E sales	4.8x	26.9x	n/m
Lead asset validation stage	Phase 2	Phase 3 win	Phase 3, mixed

On enterprise value BNTX is genuinely the cheapest of the three. On net asset value it is not cheap — because the enterprise value is low precisely because the market is discounting the burn correctly.

8. The class is not de-risked

Pumitamig carries the valuation, and the PD-(L)1 x VEGF class has sent conflicting signals throughout 2026:

Event	Read
HARMONi-6 (Akeso, China): overall survival 27.9 vs 23.7 months, HR 0.66, p=0.0017 vs tislelizumab plus chemotherapy in first-line squamous NSCLC	Class works, in China
ASCO 2026 discussant on global applicability: not yet applicable to the global patient population, pending the next wave of studies	Western translation unproven
HARMONi-3 squamous cohort missed statistical significance on progression-free survival at interim; Summit shares fell sharply	Western Phase 3 bar is high
HARMONi overall survival HR improved to 0.76 at the June 2026 cut, still not statistically significant; FDA decision due 14 November 2026	First class approval decision is the real gate

Pumitamig has only Phase 2 data. Five new pivotal trials were initiated in H1 2026 across triple-negative breast, colorectal, gastric and non-small cell lung cancer, taking the ROSETTA programme to seven pivotal trials. BioNTech is spending Phase 3 money on an asset whose class has not yet cleared a Western regulator.

Structural note: pumitamig is PD-L1 x VEGF; ivonescimab is PD-1 x VEGF. Differentiated, but that cuts both ways. The HARMONi-6 read-through is weaker than the headlines imply.

9. Catalysts

Date	Event
3 Nov 2026	Q3 results, including recognition of EUR 613m BMS collaboration revenue
14 Nov 2026	Summit / ivonescimab PDUFA. First Western approval decision for the class. The single largest read-through to pumitamig probability of success — and not BioNTech's own trial.
Q4 2026	DYNASTY-Breast02 primary analysis (trastuzumab pamirtecan, HR-positive HER2-low metastatic breast). Nearest BioNTech-owned Phase 3 readout.
2026	Gotistobart PRESERVE-003 Stage 2 first interim. Stage 1 showed overall survival HR 0.46 in post-PD-(L)1 squamous NSCLC — small N, but the best efficacy signal BioNTech owns outright.
By 1 Feb 2027	Guido Oelkers (former Sobi CEO) takes over as CEO, succeeding co-founder Ugur Sahin. Founder-to-operator handoff mid-pivot is a live execution variable.

10. Levels and thesis-break triggers

Zone	Price (USD)	Basis
Bull NAV	128	Pumitamig USD 20B peak, 60% PoS
Current	114.05	Requires above USD 32B peak at 50% PoS
PWFV	78	35 / 45 / 20 weighted
Base NAV	74	USD 9B peak, 40% PoS
Gross net cash	75	Cash before burn NPV
Accumulation zone	60-70	Below base NAV, above hard floor
Bear NAV / hard floor	45-55	Net cash less full burn NPV

Triggers set in advance

• Ivonescimab approved on 14 November with a broad label: raise pumitamig PoS to 55% or above, PWFV moves toward USD 88-95. Re-rate up.
• Ivonescimab complete response letter or narrow label: cut pumitamig PoS to 25%, PWFV toward USD 65. Sell.
• DYNASTY-Breast02 misses: cut trastuzumab pamirtecan to bear case, PWFV toward USD 72.
• FY27 adjusted R&D guided above EUR 2.3B: burn NPV worsens; each USD 1B of incremental NPV burn is approximately USD 4 per share.
• Buyback halted: management signalling capital constraint rather than confidence.

11. Where this could be wrong

1. Burn is the biggest lever and the hardest assumption. The model assumes EUR 8.9B cumulative gross burn to 2031. Management has cut adjusted R&D twice this year and states savings continue into future years. Reaching breakeven two years earlier lifts base NAV to approximately USD 83.
2. Zero value assigned to the preclinical estate, CAR-T, infectious disease and CureVac IP, while full corporate burn is charged. Deliberately conservative; probably understates NAV by USD 2-4 per share.
3. Risk-free rate is unverified. If the correct figure is 5.50%, WACC rises to 11.21% and fair value falls further, not rises. The error is asymmetric against the bull case.
4. Pumitamig milestones not valued separately. Up to USD 7.6B in development, regulatory and commercial milestones remain available beyond the USD 1.5B upfront and USD 2B non-contingent payments. Those are largely coincident with the success scenarios already captured in probability of success, so separate valuation would double-count. The non-contingent portion is embedded in the burn path.

---

Sources: BioNTech SE Form 6-K for the period ended 30 June 2026 (filed 4 August 2026); BioNTech Q1 2026 Form 6-K; Bristol Myers Squibb FY2025 Form 10-K; Alpha Vantage GLOBAL_QUOTE and CURRENCY_EXCHANGE_RATE (25-26 August 2026); ASCO 2026 and ELCC 2026 congress reporting; Summit Therapeutics disclosures.

Disclaimer: This note is independent research for informational purposes only. It is not investment advice, and it is not a recommendation to buy or sell any security. Valuation outputs depend on assumptions that are explicitly stated and may be wrong. Readers should conduct their own due diligence and consult a licensed adviser. No position disclosed.